紫龙金片联合含铂类化疗方案治疗非小细胞肺癌Meta分析

Zilongjin Tablet Combined with Platinum Chemotherapy in Non-Small Cell Lung Cancer:a Meta-Analysis

目的:系统评价紫龙金片联合含铂类化疗方案治疗非小细胞肺癌患者的有效性及安全性。方法:检索中国生物医学文献数据库(CBM),国家知识基础设施数据库(简称中国知网,China National Knowledge Infrastructure,CNKI),中文科技期刊数据库(简称维普资讯,Chinese Citation Database,CCD),中国学术期刊数据库(简称万方数据库,China Science Periodical Database,CSPD),PubMed,EMbase,CochraneLibrary,检索时限均从建库至2018年12月。按照纳排标准筛选文献,对纳入文献进行信息提取,使用Revman进行统计分析。结果:共纳入12项研究。与对照组比较,紫龙金片联合含铂类化疗方案可提高实体瘤稳定率(OR=1.91,95%CI为1.02~3.58,P=0.04),优化患者生命质量(OR=8.21,95%CI为3.24~20.78,P<0.00001),改善中医证候(OR=246.16,95%CI为70.10~864.39,P<0.00001),增强NK细胞活性(MD=8.38,95%CI为6.56~10.19,P<0.00001),提高T淋巴细胞亚群水平;与对照组比较,观察组消化系统(OR=0.43,95%CI为0.29~0.65,P<0.0001)、血液系统(OR=0.38,95%CI为0.27~0.54,P<0.0001)、肝肾功能损伤(OR=0.40,95%CI为0.19~0.87,P=0.02)的不良反应发生率较低,且差异均有统计学意义。结论:紫龙金片联合含铂类化疗方案治疗非小细胞肺癌患者具有较好的辅助治疗作用,可提高患者生命质量,改善免疫功能,临床治疗安全性较好。

Objective:To systematically review the efficacy and safety of Zilongjin Tablet combined with platinum chemotherapy in NSCLC.Methods:Literature was retrieved in CNKI,Wanfang Data,VIP,CBM,Pubmed,Embase and Cochrane library.The search time was up to December 2018.Literature was screened according to inclusion criteria,and available information included was extracted.Meta-analysis was performed by Revman 5.3.Results:A total of 12 studies were included.Compared with the control group,Zilongjin Tablets combined with platinum-containing chemotherapy can increase the stable rate of solid tumors[OR=1.91,95%CI(1.02~3.58),P=0.04],improve the quality of life[OR=8.21,95%CI(3.24~20.78),P<0.00001],relieve TCM syndrome[OR=246.16,95%CI(70.10~864.39),P<0.00001],promote activity of NK cells[MD=8.38,95%CI(6.56~10.19)P<0.00001]and improve T lymphocyte subpopulation level.Compared with the control group,digestive system in the test group[OR=0.43,95%CI(0.29~0.65),P<0.0001],blood system[OR=0.38,95%CI(0.27~0.54,P<0.0001]and hepatic and renal function[OR=0.40,95%CI(0.19~0.87),P=0.02].The incidence of adverse reactions of those was low and all are statistically significant.Conclusion:Zilongjin Tablet has better efficacy and safety when used as adjuvant therapy combine with platinum chemotherapy on treating non-small cell lung cancer.It can improve the quality of life of patients,improve the immune function,and have better clinical treatment safety.